Here’s Why PGIM Jennison Health Sciences Fund Reduced its Position in Marinus Pharmaceuticals (MRNS)
PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Marinus Pharmaceuticals Inc. (MRNS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Beryl Capital Management David Alexander Witkin | 4,227,460 | $2,262,114 | 0.51% | |
| 2. | Woodline Partners Michael Rockefeller And Karl Kroeker | 2,335,681 | $1,249,823 | +85% | 0% |
| 3. | Tang Capital Management Kevin C. Tang | 1,641,945 | $878,605 | -66% | 0.05% |
| 4. | Citadel Investment Group Ken Griffin | 501,911 | $268,573 | +109% | 0% |
| 5. | Millennium Management Israel Englander | 239,414 | $128,110 | -51% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.10 | 5,933 | Officer, Director | 304,600 | 2024-08-14 | Filing | |
| $1.25 | 100,000 | Officer, Director | 100,000 | 2019-12-13 | Filing | |
| $5.61 | 3,561 | Officer, Director | 116,085 | 2015-11-06 | Filing | |
| $8.00 | 419,744 | Large Shareholder | 2,476,886 | 2014-08-05 | Filing | |
| $8.00 | 12,528 | Large Shareholder, Director | 27,998 | 2014-08-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.54 | 1,600 | 10,900 | 2025-01-21 | Filing | ||
| $0.54 | 1,610 | 12,490 | 2025-01-21 | Filing | ||
| $1.13 | 4,657 | 79,773 | 2024-08-05 | Filing | ||
| $1.14 | 3,820 | 67,406 | 2024-08-05 | Filing | ||
| $1.13 | 3,621 | 60,263 | 2024-08-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,299,229 | $1,765,418 | 0% | |
| 2. | 2,700,000 | $1,444,770 | 0.07% | |
| 3. | 2,693,380 | $1,441,228 | 0.16% | |
| 4. | 2,658,527 | $1,422,578 | 0% | |
| 5. | 2,596,768 | $1,389,271 | 0% |
News See All
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q2 2024 Earnings Call Transcript
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q2 2024 Earnings Call Transcript August 13, 2024Marinus Pharmaceuticals, Inc. misses on earnings expectations.
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2023 Earnings Call Transcript
Marinus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.74 EPS, expectations were $-0.64. Marinus Pharmaceuticals, Inc.
5 Hyper-Growth Stocks Billionaires Are Loading Up On
This article presents an overview of the 5 Hyper-Growth Stocks Billionaires Are Loading Up On. For a detailed overview of such stocks, read our article, 11 Hyper-Growth Stocks Billionaires Are Loading...
5 Most Promising Long-Term Stocks According to Analysts
In this piece, we will take a look at the five most promising long-term stocks according to analysts.
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2023 Earnings Call Transcript
Operator: Greetings and welcome to the Marinus Pharmaceuticals' Third Quarter 2023 Financial Results and Business Update Call. [Operator Instructions].
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q2 2023 Earnings Call Transcript
Operator: Greetings and welcome to the Marinus Pharmaceuticals’ Second Quarter 2023 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode.
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q1 2023 Earnings Call Transcript
Operator: Greetings and welcome to the Marinus Pharmaceuticals’ First Quarter 2023 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode.
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2022 Earnings Call Transcript
Operator: Greetings everyone and welcome to the Marinus Pharmaceuticals' Fourth Quarter and Full-Year 2022 Financial Results and Business Update Call.
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2022 Earnings Call Transcript
Operator: Ladies and gentlemen, greetings and welcome to the Marinus Pharmaceuticals' Third Quarter 2022 Financial Results and Business Update Call.
Billionaire Hedge Funds
